1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Approval Standards

Rethinking Oncology Development: Master Protocols May Shorten Time To Approval

Master protocols that allow for the simultaneous study of multiple agents will shave more time off in the clinic than one-off studies in small groups of patients, FDA’s Janet Woodcock predicted. The current timeframes in oncology development are “unacceptable,” and can be shortened, she said, by “doing things differently.”

FDA Center for Drug Evaluation & Research Director Janet Woodcock, MD, gave some advice to drug developers looking to shorten the clinical development time for new treatments, particularly in oncology: it will be participation in innovative combination trials that will really cut development time – not simply conducting smaller, shorter studies of single agents.

Woodcock used the platform of an April 12 Friends of Cancer Research forum on Breakthrough Therapies to continue to push...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approval Standards

More NME Reviews, Reduced Costs Combine To Lower US FDA Voucher Fee

 
• By Derrick Gingery

The FDA said new molecular entity application reviews increased and cost less in fiscal year 2024, a potentially encouraging sign for industry.

US FDA Complete Response Letters Offer ‘Path Forward’ To Approval

 
• By Sue Sutter

Recently released CRLs for unapproved products contain recommendations for new studies, including design element details and advice to consider different submission pathways.

US FDA Complete Response Letters Raise Confirmatory Evidence Shortfalls

 
• By Sue Sutter

The agency identified deficiencies in efficacy evidence intended to support results from a single adequate and well-controlled trial for orphan applications, including weaknesses in animal data and insufficient quantity and quality of biomarker data.

Diving Into US FDA’s Newly Public CRLs

 
• By Bridget Silverman

The Pink Sheet breaks down the data on the 89 complete response letters recently released by the FDA, including by type of application and problems noted.

More from Pathways & Standards

US FDA Complete Response Letters Offer ‘Path Forward’ To Approval

 
• By Sue Sutter

Recently released CRLs for unapproved products contain recommendations for new studies, including design element details and advice to consider different submission pathways.

Blueprint For RWE: Aetion Execs Outline Real-World Data Role From Preclinical To Postmarketing

 
• By Bridget Silverman

Sponsors should systematically incorporate real-world evidence generation in all development programs, advises an epidemiology-forward “blueprint” Aetion executives developed.

US FDA Complete Response Letters Raise Confirmatory Evidence Shortfalls

 
• By Sue Sutter

The agency identified deficiencies in efficacy evidence intended to support results from a single adequate and well-controlled trial for orphan applications, including weaknesses in animal data and insufficient quantity and quality of biomarker data.